<DOC>
	<DOCNO>NCT01129882</DOCNO>
	<brief_summary>Purpose : To continue provide aripiprazole intramuscular ( IM ) Depot treatment ( 400 mg 300 mg ) subject schizophrenia complete 52-week , open-label safety tolerability Study 31-08-248 .</brief_summary>
	<brief_title>An Open-Label , Multicenter , Rollover , Long-term Study Aripiprazole Intramuscular Depot Patients With Schizophrenia</brief_title>
	<detailed_description>This open-label study enroll subject schizophrenia complete 52-week , open-label safety tolerability Study 31-08-248 continue provide aripiprazole intramuscular ( IM ) Depot treatment . Subjects receive treatment aripiprazole IM Depot commercially available dosage ( include generic formulation ) country study conduct commercial availability aripiprazole IM Depot terminate sponsor , study end date 31 Dec 2018 reach . Eligible subject enter study End Treatment visit ( Week 52 ) Study 248 . Subjects continue receive aripiprazole IM Depot every month ( study month every 4 week define 28 [ -2/+10 ] day ) continuation previous monthly dose Study 248 .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Subjects current diagnosis schizophrenia , define DSMIVTR criterion , complete openlabel extension Study 248 ( complete Study 248 study completion visit , Week 52 ) . Subjects , investigator 's judgment , may benefit continued participation aripiprazole IM Depot study . The baseline visit Study 270 ( Week 52 visit Study 248 ) first injection Study 270 must occur within 4 week ( define 28 [ 2/+10 ] day ) last injection Study 248 . Subjects able provide write informed consent and/or consent obtain legally acceptable representative ( require IRB/IEC ) , prior initiation protocolrequired procedure . Subjects able understand nature study follow protocol requirement read understand write word order complete patientreported outcome measure . Outpatient status . Subjects current DSMIVTR diagnosis schizophrenia , include schizoaffective disorder , MDD , bipolar disorder , delirium , dementia , amnestic cognitive disorder . Also , subject borderline , paranoid , histrionic , schizotypal , schizoid antisocial personality disorder . Subjects currently meet DSMIVTR criterion substance dependence ; include alcohol benzodiazepine , exclude caffeine nicotine . Subjects significant risk violent behavior significant risk commit suicide base investigator 's judgment . Subjects know allergic , intolerant , unresponsive prior treatment aripiprazole quinolinones . Subjects history neuroleptic malignant syndrome clinically significant tardive dyskinesia screening . Electroconvulsive therapy within 180 day prior entry . Any subject require may need antipsychotic medication course study . Aripiprazole IM Depot ( include generic formulation ) commercially available subject 's country . Other protocol specific inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Schizophrenia</keyword>
</DOC>